Introduction
tors was performed by flow cytometry in different disease categories, ie AML (n ‫؍‬ 72), ALL (n ‫؍‬ 18), and MDS (n ‫؍‬ 12), as
In the last few years, the molecular cloning and purification well as 12 healthy volunteers, using three different unconjuof several hemopoietic growth factors (GF) and cytokines,
gated GM-CSF/R monoclonal antibodies (McAbs) (HGM-CSFR
such as the granulocyte colony-stimulating factor (G-CSF), does not bind GM-CSF, but its association with the alpha-sub-AML patients were treated with a DAT (daunorubicin, cytosine arabinoside, thioguanine)-based induction regimen, folunit generates high affinity receptors for GM-CSF. At the 5th International Workshop on Leukocyte Differentiation Antigens lowed by consolidation chemotherapy. Patients with ALL of B lineage (pro-B subtype) were treated according to a standard held in Boston, MA, USA, in November 1993, this molecule was termed CDw116. 30, 33 The CDw (w stands for workshop) protocol based on the sequential use of daunorubicin, vincristine, cytosine arabinoside, cyclophosphamide, prednisone designation has been given to this receptor as its reactivity has not yet been completely defined, and therefore will have to and asparaginase. be re-evaluated in future workshops. Nevertheless, extensive multidisciplinary studies which included flow cytometry, biochemical, molecular, histochemical and serologic analysis Flow cytometry analysis have allowed the identification of one McAb specific for the GM-CSF receptor (HGM-CSFR). Other McAbs, although givWhole blood samples and purified CD34 + cells were analyzed with a FacScan flow cytometer (Becton Dickinson, San José, ing rise to conflicting results when evaluating McAbs reactivity with cells transfected with CD116 cDNA and binding to CA, USA) equipped with a 15 W argon-ion laser. The instrument was calibrated with FITC (isothyocyanate of fluorescein) GM-CSF protein, showed a pattern of reactivity rather similar to that of the reference HGM-CSFR McAb. 30 The recent availand PE (R-phycoerythrin) beads provided by Becton Dickinson. Data were analyzed with appropriate negative (isotypic) ability of quantitative microbead calibration standards has allowed a precise, reproducible cytofluorimetric quantitation and positive (blood cells from healthy adult subjects) controls using Lysis II and Paint-a gate research software. Twenty thouof the number of receptors per cell exhibited by cell populations labeled with monoclonal antibodies directed against sand cells were analyzed for each sample at a flow rate of approximately 300 particles per s. 38 different cytokine receptors. 34 The microbeads are to be considered reference standards which allow the comparison
The blast cell population was identified using a combined approach based on a multicolor analysis and evaluation of between the fluorescence intensity showed by cells stained with a given McAb and that of the four-or five-bead populight scattering properties of the cells (forward scatter and side scatter). 39 lations. The use of microbeads also makes it possible to compare the flow cytometry data over time, and between one labFlow cytometry analysis of GM-CSF receptor on CD34
+ bone marrow cells obtained from healthy subjects has been oratory and another. [34] [35] [36] In order to investigate the clinical applicability and safety performed using a multiparametric live-gate approach. In three cases, the cytofluorimetric analysis was also performed of GM-CSF therapy in patients with neoplasms of the myeloid compartment, and possibly to optimize its use in the clinical on CD34 + cells which were purified using a positive selection technique (Dynabeads; Dynal, Oslo, Norway). 35, 40 setting, we evaluated the cytofluorimetry expression of GM-CSF receptors in cells from patients with AML (n = 72), ALL Flow cytometry data were expressed as percentage of positivity (using the standard marker approach), as molecules of (n = 18), MDS (n = 12), and from 12 healthy subjects. The number of GM-CSF receptors per cell was measured with a equivalent soluble fluorochrome (MESF), and as antibody binding capacity (ABC). FacScan flow cytometer, using quantitative calibration microbeads which allowed a precise calculation of the numBased on the analysis of the minimum detection threshold of our flow cytometer, and on variation in ABC value for GMber of GM-CSF/R per cell in the various populations analyzed.
CSF/R in control and pathological samples (evaluated within and between different specimens), we estimated that the lower limit of quantitation was 500 molecules/cell, which correMaterials and methods sponded to 1.0 × 10 3 , MESF/cell. Below this limit the enumeration of antigenic determinants was considered unreliable, Subjects and unreproducible. However the lower limit of detection was variable and ranged from 390 to 550 molecules/cell. Fresh bone marrow (BM) cells obtained from patients with acute myeloid leukemia (n = 72), and acute lymphoblastic leukemia (n = 18) were investigated within 4 h from their collection. Peripheral blood cells from 12 patients with myeloImmunophenotypic analysis dysplastic syndromes, were also included in this study.
Peripheral Experiments of single, double, and triple staining were higher than 60% in the specimen analyzed (mean 76%).
According to FAB criteria, patients with MDS were distribemployed in all cases. uted as follows: refractory anemia (RA) (n = 6), refractory anemia with excess of blasts (RAEB) (n = 4), RAEB in transformation (RAEB-t) (n = 2).
Monoclonal antibodies to GM-CSF/R
The diagnosis of byphenotypic leukemias or AML with minimal phenotypic deviation was made according to the pro-
The expression of GM-CSF/R on normal and leukemic cells was assessed by using three different Two monoclonal antibodies PAb 1801 and PAb 240 (Oncogene Science, Cambridge, UK), were used to detect p53 coefficient allow the calculation of the regression line, which gives information on the linearity and stability of the instruexpression. The antibody PAb 1801 recognized an epitope near the NH2-terminal end of the p53 peptide present in all ment response, the noise level of the flow cytometer, the MESF values of the stained and unstained cells, the resolution species studied; it reacts preferentially with human p53. The antibody PAb 240 was originally reported to recognize a comindexes for fluorescence, and the coefficient of variation (CV) of microbeads fluorescence. 35 The minimum detection thresmon conformational epitope closely associated with undenatured wild-type p53 protein in hemopoietic cells. hold of the instrument corresponds to the MESF value for the blank beads, and provides information on the sensitivity of For the detection of p53 expression by flow cytometry, cells were first fixed at −8°C to −10°C for 5 min in paraformthe flow cytometer in detecting fluorescence signals, which resulted for our FacScan within 130-310. Based on the aldheyde-lysine-periodate (PLP) fixation solution. 40, 42 After removal from the fixation solution, cells were washed in phosprotein/fluorochrome ratio of the second step, the antibody binding capacity may be calculated for each cell population.
phate-buffered saline and incubated with one or another of the p53 monoclonal antibodies for 30 min at 4°C, washed After data acquisition, the microbeads were run again, in order to see whether any significant changes in MESF values in phosphate-buffered saline, and incubated with fluorescein isothiocyanate-conjugated rabbit antimouse IgG monoclonal occurred. In that case, MESF calculation of the sample was corrected accordingly.
antibody (Dakopatts) before incubation with the conjugated secondary antibody. Flow cytometric analysis was carried out For each sample, the MESF value of the isotypic control was reduced from the MESF value of the positive cell population.
on a FacScan flow cytometer.
Assessment of DNA content by flow cytometry QIFIKIT:
Starting from the beginning of 1995, normal and acute leukemic samples were also analyzed by using the DAKO QIFIKIT (Dakopatts). This kit contains a series of beads
The assessment of cellular DNA content was made with a FacScan flow cytometer (Becton Dickinson Cell proliferation studies 49 .6 ± 10 s.d.) and Li − (2.9 ± 1.9 s.d.) CD34 + cells. Furthermore, the expression levels of GM-CSF/R of normal Bromodeoxyuridine incorporation and a monoclonal antibody against bromodeoxyuridine (Becton Dickinson) in conhemopoietic cells did not show any positive correlation with the number of CFU-GM or CFU-GEMM colonies, or with junction with flow cytometry were used to calculate the size of population of cells in S-phase of the cell cycle. For labeling active cell cycle phases. cells and detection we used a previously published method. 41 
Analysis of GM-CSF-receptor in MDS cells Chromosome analysis
The number of GM-CSF/R expressed by neutrophil granulocytes and monocytes from patients with MDS was significantly Cytogenetic studies of leukemic cells were performed at leukemia diagnosis to detect the presence of structural or numerilower than that of their normal counterparts; this reduction was more prominent in patients with a bone marrow blast cal abnormalities. It was based on both a direct technique or a short-term culture. Synchronization with methotrexate and percentage higher than 10% of nucleated cells ( 
The flow cytometry data derived from the quantitative analysis of expression levels of GM-CSF receptors in peripheral blood
In AML, no correlation was found between the number of GM-CSF/R and kinetic status, DNA content, p53 protein and bone marrow cells from 12 healthy donors are shown in Table 1 . The number of receptors per cell was four-fold higher expression, and cytogenetic abnormalities (P and r values not significant; data not shown). in monocytes than in neutrophil granulocytes, whereas lymphocytes did not express detectable levels of GM-CSF recepIn AML, there was no difference in overall survival and complete remission rates between patients whose blasts cells tors.
As far as the cytofluorimetric expression of GM-CSF/R in expressed GM-CSF/R (n = 56) and those who resulted GM-CSF/R negative (n = 16) (data not shown). bone marrow cells is concerned, we found that myeloid precursors (promyelocytes, myelocytes, and metamyelocytes) Blast cells from all but two ALL patients were GM-CSF/R negative. However, the number of receptors detected in GM-CSF/R + showed intermediate levels of GM-CSF/R (range of MESF/cell: 11.7 × 10 3 -40.5 × 10 3 ABC), as demonstrated by two-and ALL patients was extremely low (Ͻ1000 ABC/cell; Ͻ2300 MESF/cell). In the first case, we observed a co-expression of three-color fluorescence analysis (CD33, HGM-CSFR, CD45). Monocytes and their precursors showed higher levels of GMmyeloid (CD13 and CD33) and lymphoid markers (CD10, CD19, CD79␣, CD22). The remaining case was classified as CSF/R (MESF range: 25.7 × 10 further showed that the number of receptors expressed by five Interestingly, in three AML patients, relapsed disease after induction-consolidation chemotherapy was characterized by a out 72 (7%) AML cases was above the highest values seen in normal samples (Ͼ69.2 × 10 3 MESF/cell; range, 77.3 × 10 3 -two-fold increase in GM-CSF receptor number (mean pre-treatment ABC values: 3.5 × 10 3 /cell; mean ABC value in relapsed 106.7 × 10 3 ). All these cases were found within the M5 FAB subtype, where receptor overexpression was noticed in 25% of disease: 7.3 × 10 3 /cell). In the same cases, we observed a marked increase in the number of proliferating cells, ie S-G2+M the cases examined (Figure 2 Cell culture studies aimed at evaluating GM-CSF receptor modulation following AML blast exposure to GM-CSF showed two The statistical analysis of 22 samples showed that both the indirect immunofluorescence staining in the Quantum beads distinct patterns of response: in the first group of patients (n = 6), GM-CSF down-modulated GM-CSF receptors, while in the assay, and that in the QIFIKIT assay give comparable quantitative data. A positive correlation was noticed between both MESF second group, the administration of GM-CSF was associated with either an increase (n = 2) or no change (n = 2) in the numand ABC values in the Quantum assay, and ABC in the QIFIKIT (r = 0.992, and r = 0.99, respectively) ( Figure 3) .
ber of GM-CSF/R ( Figure 4) . In brief, when incubated in the pres-
Figure 2
Expression levels of GM-CSF receptors in AML blasts according to the FAB subtype (box plot representation). Data were obtained using the HGM-CSFR McAb (CD116). Acute leukemic blasts from five AML patients with M5 FAB subtype had a number of GM-CSF/R significantly higher than that of normal bone marrow hemopoietic cells. Vertical axis, ABC value.
Table 1
Flow
cytometry quantification of GM-CSF/R in normal and MDS peripheral blood cells using HGM-CSFR McAb and Quantum beads
Cell population GM-CSF/R expression in PB and P value GM-CSF/R expression in PB BM and BM cells from MDS hemopoietic cells from healthy adults The range for ABC and MESF values refers to positive cases. BM, bone marrow; PB, peripheral blood; ND, = not done; MDS, myelodysplastic syndrome; RA, refractory anemia; RAEB, refractory anemia with excess of blasts; NS, not significant. ence of rhGM-CSF, leukemic cells from six AML patients in acute leukemia patients was investigated. [45] [46] [47] [48] [49] [50] To detect the receptor for GM-CSF, three different unconjugated GM-CSF/R showed a 71% down-regulation of GM-CSF/R; this decrease was statistically significant (P Ͻ 0.001). In contrast, no significant
McAbs were used (HGM-CSFR, M5D12, 4B5F5) in conjunction with a flow cytometer and appropriate standards. Flow cytomechanges were observed in cell cultures obtained from leukemic cells incubated without rhGM-CSF. In two cases, a 37% uptry data were expressed in the form of both MESF and ABC/cell through the use of FITC-pre-mixed quantitative microbead caliregulation of GM-CSF/R was observed after priming AML cells with rhGM-CSF.
bration standards, and QIFIKIT calibration beads. [34] [35] In healthy subjects, reactivity for HGM-CSF/R McAb was detected on peripheral blood monocytes, neutrophils, and bone marrow (BM) myelo-monocytic precursors. In addition, two disDiscussion tinct subsets of normal BM CD34 + progenitors showed positivity for HGM-CSFR McAb: GM-CSF/R dim , and GM-CSF/R bright (10% In this study, a quantitative cytofluorimetric analysis of the expression levels of GM-CSF/R was carried out on patients affecof the total number of CD34 cells). GM-CSF/R bright cell fraction was found within both Li + and Li − CD34 + cells; similarly, a GMted by various hematological malignancies (AML, ALL, MDS), and on 12 healthy adult volunteers, with the aim of providing CSFR dim subset was identified in Li + and Li − CD34 + cells. Furthermore, in healthy donors there was no correlation between the a better selection of patients with clonal myeloid disorders who may be eligible for GM-CSF treatment.
43, 44 Moreover, the bionumber of GM-CSF/R detected by flow cytometry, CFU-GM/CFU-GEMM colony production, or cell cycle phases. These logic and clinical significance of GM-CSF receptor expression Table 2 Flow cytometry quantification of expression levels of GM-CSF/R in acute leukemic blasts of myeloid (AML), B lymphoid (B-ALL) and mixed lineage (BAL) (data obtained using . In AML, GM-CSF/R expression did not correlate with kinetic status, DNA content, p53 protein neutrophil granulocytes and, to a lesser extent, by monocytes from MDS patients was significantly lower than that from their expression, or cytogenetic abnormalities. On the contrary, only 2/18 cases of B lineage ALL showed a normal counterparts; this reduction was more prominent in patients with a bone marrow blast percentage over 10% of the dim GM-CSF/R positivity. Recent reports have shown that GM-CSF receptors can be found on some normal and leukemic lymnucleated cells. Furthermore, the flow cytometry analysis showed that 80% of MDS patients presented a loss of GM-CSF phocytes, allowing the authors to speculate that receptor expression is a stage-specific feature of late B cells. 48 There is receptors in 6-73% of cells.
Among AML samples, M5D12 McAb was positive in 33%, evidence that GM-CSF receptors are sometimes detectable in acute leukemic blasts of lymphoid lineage, thus supporting the 4B5F5 McAb in 90%, and H-GMCSF/R McAb in 78% of the cases examined. However, whereas 58% of patients from M0-concept that a small number of non-functional GM-CSF receptors may be detected in the early phases of lymphocyte commit-M1 and M2 FAB subtypes expressed GM-CSF/R in over 40% of leukemic cells, all patients with M5 FAB subtypes showed posiment. 30 Furthermore, the quantitative analysis of GM-CSF/R in acute tivity for HGM-CSF/R McAb in the majority (Ͼ80%) of blast cells. Furthermore, blasts from FAB M5 AML were characterized leukemia has shown that the number of receptors expressed by five out of 72 (7%) AML cases was above the highest values by the highest receptor numbers, thus supporting the concept that a close association between the monocytic commitment seen in normal samples, allowing the possibility of using this marker for the monitoring of the minimal residual disease (MRD) and expression of GM-CSF/R may exist. In most cases of M1- in a subset of AML. Another interesting finding which may have liferation (autocrine effect). 2, 3, 58 This effect can be interrupted by the administration of exogenous growth factors. 58 clinical implications is represented by the marked increase in the number of GM-CSF receptors in relapsed disease after inducIn this paper, we have demonstrated that the exposure of GM-CSF/R + AML blasts to rhGM-CSF induced a 71% down-regution-consolidation chemotherapy. In our cases, this finding was associated with a significant increase in the blast cell proliferlation of GM-CSF receptors in 60% of the cases examined, while in the remaining cases the administration of rhGM-CSF was ation rate, thus suggesting that the quantitative analysis of this receptor may be valuable for the monitoring of AML patients. associated with either an increase (37% up-regulation) or no change in the number of GM-CSF/R. These data may have cliniConcerning the clinical implication of GM-CSF receptor studies in AML patients, it is likely that new insights into the use of cal and therapeutic relevance, as GM-CSF is currently being used in patients with acute leukemia to shorten the duration of rhGM-CSF in myeloid malignancies may derive from in vivo and in vitro studies aimed at evaluating GM-CSF receptor moduneutropenia following chemotherapy, or to recruit blast cells into active cell cycle phases when administered before chemolation, following exposure of cells to GM-CSF. [51] [52] [53] [54] [55] [56] [57] [58] Some recent papers have shown that the affinity status and/or number of therapy. We personally believe that the dynamic evaluation of the receptor status on the blastic and 'supposed' normal cell receptors can be significantly modified after treatment with GM-CSF. 51, 53 There is also evidence that AML and MDS blasts not population represents a promising tool for optimizing GM-CSF treatment in patients with acute leukemias, making the analysis only express GM-CSF receptors but also synthesize GM-CSF themselves; as a consequence, they can stimulate their own proof data from clinical trials based on the combined use of chemotherapy and GM-CSF more accurate and meaningful.
